Schneeberger Daniel's Form 4 filing
NextCure, Inc. (NXTC) · filed Aug 3, 2026
- Accession no.
- 0001940272-26-000013
- Filed
- Aug 3, 2026, 5:53 PM ET
- Trade date
- Jul 30-31, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions. Open-market purchases total $1.62M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schneeberger DanielCIK 0001861120 | 10% Owner |
| ADAR1 Capital Management, LLCCIK 0001940272 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +50,000 | $4.97F1 | +$248,615 | 443,266 | Indirect | |
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +20,000 | $5.00 | +$100,000 | 463,266 | Indirect | |
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +20,000 | $5.00 | +$100,000 | 483,266 | Indirect | |
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +25,000 | $4.81F2 | +$120,337.5 | 508,266 | Indirect | |
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +100,000 | $4.90 | +$490,000 | 608,266 | Indirect | |
| Jul 30, 2026 | Common Stock | PPurchaseAcquired | +77,850 | $4.96F3 | +$385,793.46 | 686,116 | Indirect | |
| Jul 31, 2026 | Common Stock | PPurchaseAcquired | +3,300 | $4.98F4 | +$16,420.14 | 689,416 | Indirect | |
| Jul 31, 2026 | Common Stock | PPurchaseAcquired | +25,000 | $4.98F5 | +$124,540 | 714,416 | Indirect | |
| Jul 31, 2026 | Common Stock | PPurchaseAcquired | +8,003 | $4.80 | +$38,414.4 | 722,419 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.